These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33568438)

  • 21. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female
    Zimovjanova M; Bielcikova Z; Miskovicova M; Vocka M; Zimovjanova A; Rybar M; Novotny J; Petruzelka L
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer.
    Heiniger L; Butow PN; Coll J; Bullen T; Wilson J; Baylock B; Meiser B; Price MA
    Fam Cancer; 2015 Mar; 14(1):105-15. PubMed ID: 25283514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    Loizzi V; Cicinelli E; Del Vecchio V; Arezzo F; Deromemaj X; Kardhashi A; Paradiso A; Legge F; Natalicchio MI; Resta L; Resta N; Loconte DC; Cormio G
    Acta Biomed; 2022 Aug; 93(4):e2022051. PubMed ID: 36043985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical decision making in premenopausal
    Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
    J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
    Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
    Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline
    Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M
    Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study.
    Grandi G; Del Savio MC; Sammarini M; Cortesi L; Toss A; Piombino C; Facchinetti F
    Eur J Cancer Prev; 2020 Jul; 29(4):350-356. PubMed ID: 32516171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    Conley CC; Kasting ML; Augusto BM; Garcia JD; Cragun D; Gonzalez BD; Kim J; Ashing KT; Knott CL; Hughes-Halbert C; Pal T; Vadaparampil ST
    Ann Surg Oncol; 2020 May; 27(5):1659-1670. PubMed ID: 31677107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    Park B; Kim D; Kim J; Lee BY; Yoon J; Kim SW
    Cancer Res Treat; 2022 Apr; 54(2):375-382. PubMed ID: 34384016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    Mavaddat N; Antoniou AC; Mooij TM; Hooning MJ; Heemskerk-Gerritsen BA; ; Noguès C; Gauthier-Villars M; Caron O; Gesta P; Pujol P; Lortholary A; ; Barrowdale D; Frost D; Evans DG; Izatt L; Adlard J; Eeles R; Brewer C; Tischkowitz M; Henderson A; Cook J; Eccles D; ; van Engelen K; Mourits MJE; Ausems MGEM; Koppert LB; Hopper JL; John EM; Chung WK; Andrulis IL; Daly MB; Buys SS; ; Benitez J; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Van Leeuwen FE; Arver B; Olsson H; Schmutzler RK; Engel C; Kast K; Phillips KA; Terry MB; Milne RL; Goldgar DE; Rookus MA; Andrieu N; Easton DF; ; ;
    Breast Cancer Res; 2020 Jan; 22(1):8. PubMed ID: 31948486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
    Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
    BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
    Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
    Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    Ladd MK; Peshkin BN; Senter L; Baldinger S; Isaacs C; Segal H; Philip S; Phillips C; Shane K; Martin A; Weinstein V; Pilarski R; Jeter J; Sweet K; Hatten B; Wurtmann EJ; Phippen S; Bro D; Schwartz MD
    Transl Behav Med; 2020 May; 10(2):337-346. PubMed ID: 30418620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.